Andy Sidler

A judge hearing a class action against J&J over allegedly ineffective cold medications has questioned the merits of soft class closure in large consumer cases where participation is likely be low, just days after another judge raised similar concerns in a case against Toyota. 

AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege. 

The former Australian head of HR at real estate giant Jones Lang LaSalle has sued her former employer, alleging she was unfairly sacked in the fallout of a harassment investigation against an executive, despite having recommended his dismissal. 

A judge has granted most of the documents sought by a shareholder class action against Origin Energy but declined to make a ‘safety net’ discovery order, agreeing with the energy company that it was unnecessary. 

A judge has rejected a bid by Toyota's finance arm to require group members in two class actions to register ahead of mediation to participate in any settlement arising from mediation in the cases.

The former Australian head of HR at Jones Lang LaSalle claims she was ostracized and unfairly sacked in the wake of a harassment investigation into a senior manager, which sparked a media frenzy Australian leadership was allegedly told to "ignore".

A community group is seeking to quash a decision approving Southern Cross Gold’s Sunday Creek exploration tunnel project 60 km north of Melbourne, arguing that its concerns about the environment and noise were ignored. 

A leading competition law barrister has been appointed as the federal government’s chief legal advisor, with the government’s kids social media ban and attacks on hate speech laws to be among her early challenges. 

A former director of collapsed Melbourne builder Shangri-La is being pursued by liquidators for $1.3 million in payments to related companies allegedly made in breach of his duties. 

Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.